Tanespimycin (17-AAG) is a potent N-terminal HSP90 inhibitor. It affects AKT/GSK3β, JAK/STAT, and MAPK signaling pathways by inhibiting HSP90 chaperone function and degrading client proteins, effectively inhibiting cell proliferation, migration, and viral replication, and promoting apoptosis.
Tanespimycin (17-AAG) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Tanespimycin (17-AAG) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- Tanespimycin (17-AAG) Mechanism of Action: HSP90 Inhibition in Tumor Cell Research
- Tanespimycin (17-AAG) Clinical Trials
- Tanespimycin (17-AAG) Working Concentration | Cell Culture | Treatment
- Tanespimycin (17-AAG) Solubility in DMSO
- Tanespimycin (17-AAG) Stock Solution
- Tanespimycin (17-AAG) Storage
- Tanespimycin (17-AAG) Stability
- Tanespimycin (17-AAG) Combination Database
- Tanespimycin (17-AAG) Molecular Weight
- Tanespimycin (17-AAG) SMILES
- Tanespimycin (17-AAG) CAS Number
- Tanespimycin (17-AAG) Chemical Structure (2D and 3D)
- Tanespimycin (17-AAG) Sigma (A8476)? Try a better option.
- Tanespimycin (17-AAG) MedChemExpress (HY-10211)? Try a better option.
- Tanespimycin (17-AAG) Cayman (11039)? Try a better option.
- Tanespimycin (17-AAG) APExBIO (A4054)? Try a better option.
- Tanespimycin (17-AAG) SDS｜MSDS